Systemic Anti-Cancer Therapy Regimen Library
LEU AML - low dose cytarabine
Treatment Overview
Frequency of cycles can be variable and may be repeated once every 28 to 42 days depending on clinical response and patient factors.
Cycle 1 (and all further cycles) - 28 days
Cycle details
Cycle 1 (and all further cycles) - 28 days
| Medication | Dose | Route | Days | Max Duration |
|---|---|---|---|---|
| cytarabine | 20 mg/m² Once daily | subcutaneous injection | 1 to 10 |
Full details
Cycle 1 (and all further cycles) - 28 days
Day: 1
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| cytarabine | 20 mg/m² Once daily | subcutaneous injection |
Day: 2
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| cytarabine | 20 mg/m² Once daily | subcutaneous injection |
Day: 3
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| cytarabine | 20 mg/m² Once daily | subcutaneous injection |
Day: 4
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| cytarabine | 20 mg/m² Once daily | subcutaneous injection |
Day: 5
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| cytarabine | 20 mg/m² Once daily | subcutaneous injection |
Day: 6
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| cytarabine | 20 mg/m² Once daily | subcutaneous injection |
Day: 7
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| cytarabine | 20 mg/m² Once daily | subcutaneous injection |
Day: 8
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| cytarabine | 20 mg/m² Once daily | subcutaneous injection |
Day: 9
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| cytarabine | 20 mg/m² Once daily | subcutaneous injection |
Day: 10
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| cytarabine | 20 mg/m² Once daily | subcutaneous injection |
Supportive Care Factors
| Factor | Value |
|---|---|
| Antifungal prophylaxis: | Routine antifungal prophylaxis may be considered |
| Antiviral prophylaxis for herpes virus: | Routine antiviral prophylaxis may be considered |
| Emetogenicity: | Minimal |
| Tumour lysis syndrome prophylaxis: | Variable |
Antiviral prophylaxis for hepatitis B virus: Guidance is limited to high-risk anti-cancer medicines. Clinicians will need to assess individual patient risk for other anti-cancer medicines.
Tumour lysis syndrome prophylaxis: Recommended for first cycle of treatment and only for further cycles if not in complete remission.
References
VIALE-C - Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135:2137–45.
Regimen details sometimes vary slightly from the published literature after recommendation by expert committee consensus.
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.